Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 14/20 | 0.45 |
| ▸ | KDR | P35968 | 12/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.45 |
| ▸ | JAK3 | P52333 | 10/20 | 0.45 |
| ▸ | BRAF | P15056 | 3/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.39 |
| ▸ | YAP1 | P46937 | 1/20 | 0.39 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.38 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30868579 | 1.00 | LCK (0.45) | LCKKDRMAPK14JAK3BRAF | |
| SCHEMBL24631203 | 0.84 | BRD4 (0.39) | TEAD1YAP1SCN9A | |
| SCHEMBL30868590 | 0.84 | BRD4 (0.39) | TEAD1YAP1SCN9A | |
| SCHEMBL30868598 | 0.83 | TEAD1 (0.42) | TEAD1YAP1SCN9A | |
| SCHEMBL24631413 | 0.83 | TEAD1 (0.42) | TEAD1YAP1SCN9A | |
| SCHEMBL24631406 | 0.83 | SCN9A (0.41) | BRAFTEAD1YAP1SCN9A | |
| SCHEMBL30868606 | 0.83 | SCN9A (0.41) | BRAFTEAD1YAP1SCN9A | |
| SCHEMBL24631201 | 0.80 | TRPV1 (0.46) | TEAD1YAP1SCN9A | |
| SCHEMBL30868586 | 0.80 | ALOX5AP (0.42) | TEAD1YAP1SCN9A | |
| SCHEMBL30868602 | 0.80 | TRPV1 (0.46) | TEAD1YAP1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083903-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | MERCK SHARP & DOHME LLC (US) | 2024-03-14 | — | — | US | claimed |
| US-20240083903-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | MERCK SHARP & DOHME LLC (US) | 2024-03-14 | — | — | US | disclosed |
| WO-2022177869-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | MERCK SHARP & DOHME LLC (US) | 2022-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083903-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | TEAD2, TEAD3, TEAD4 | LCK 682/4885KDR 3560/4885MAPK14 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.